Finanzierungen und Anlageprodukte

Steuern

Apellis_web_640x140

Homburger News

Share-Image Teamplate Deals-and-Cases

On May 13, 2024, Apellis Pharmaceuticals completed Apellis group's USD 475 m senior secured credit facilities financing

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

On May 13, 2024, Apellis Pharmaceuticals completed Apellis group&#8217;s USD 475 m senior secured credit facilities financing. Homburger advised Apellis with respect to all Swiss legal aspects of the transaction.
The Apellis group, centered around Apellis Pharmaceuticals, Inc., is a leading biopharmaceutical company specializing in the development and commercialization of therapeutic compounds aimed at treating a range of serious diseases. The group focuses on advancing innovative therapies targeting the complement system and is renowned for its pioneering work in ophthalmology and hematology.
The Homburger team was led by Daniel Haeberli and included Laura Müller, Yulia Shaburnykova (all Financing) and Stefan Oesterhelt (Tax).

Kapitalmarkt

Homburger and UBS Group AG

On February 21, 2024, UBS Group AG successfully completed its offering of SGD 650 m of 5.750 per cent. AT1 Notes, which are redeemable at the option of UBS Group AG for the first time after five years and six months.
The Notes are «high trigger» regulatory capital instruments that are eligible to fulfill UBS Group AG’s Swiss going concern requirements.
While the Notes are initially subject to write-down in accordance with their terms upon occurrence of a «Trigger Event» or a «Viability Event», the terms of the Notes provide that, following approval of a minimum amount of conversion capital by UBS Group AG&#8217;s shareholders, upon occurrence of such an event, the Notes will be converted into ordinary shares of UBS Group AG in accordance with their terms rather than be subject to write-down.
The Notes are governed by Swiss law and have been provisionally admitted to trading, and application has been made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange.
Homburger advised UBS with respect to all regulatory, transactional and tax aspects of Swiss law. The Homburger team was led by Benedikt Maurenbrecher and Stefan Kramer, and included Lee Saladino, Daniel Hulmann and Yulia Shaburnykova (all Capital Markets), as well as Stefan Oesterhelt (Tax).

Homburger advised UBS Group AG on its issuance of USD 650 m Additional Tier 1 (AT1) Notes with an equity conversion feature

On February 12, 2024, UBS Group AG successfully completed its offering of USD 1 bn of 7.750 per cent. AT1 Notes, which are redeemable at the option of UBS Group AG after seven years and two months.
The Notes are «high trigger» regulatory capital instruments that are eligible to fulfill UBS Group AG’s Swiss going concern requirements.
While the Notes are initially subject to write-down in accordance with their terms upon occurrence of a «Trigger Event» or a «Viability Event», the terms of the Notes provide that, following approval of a minimum amount of conversion capital by UBS Group AG&#8217;s shareholders, upon occurrence of a such an event, the Notes will be converted into ordinary shares of UBS Group AG in accordance with their terms rather than be subject to write-down.
The Notes are governed by Swiss law and have been provisionally admitted to trading, and application has been made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange.
Homburger advised UBS with respect to all regulatory, transactional and tax aspects of Swiss law. The Homburger team was led by Benedikt Maurenbrecher and Stefan Kramer, and included Lee Saladino, Daniel Hulmann and Yulia Shaburnykova (all Capital Markets), as well as Stefan Oesterhelt (Tax).

Yulia
Shaburnykova

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

Homburger advised UBS Group AG on its issuance of USD 650 m Additional Tier 1 (AT1) Notes with an equity conversion feature

Homburger advised UBS Group AG on its issuance of USD 1 bn Additional Tier 1 (AT1) Notes with an equity conversion feature

Join the Team

Yulia Shaburnykova

Karriere

Sprachen

Teams

YuliaShaburnykova

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

Homburger advised UBS Group AG on its issuance of USD 650 m Additional Tier 1 (AT1) Notes with an equity conversion feature

Homburger advised UBS Group AG on its issuance of USD 1 bn Additional Tier 1 (AT1) Notes with an equity conversion feature

Join the Team

Yulia Shaburnykova

Karriere

Sprachen

Teams

Yulia
Shaburnykova